Thomas J. Rutherford, MD, PhD
Director Gynecologic Oncology
Yale University School of Medicine
333 Cedar Street, Box 208063
New Haven,
CT
USA
06520-8063
Papers:
136 - Scientific Plenary
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 m
167 - Poster Session A
Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: an institutional experience
241 - Poster Session A
Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo
Late Breaking Abstract 1
A Randomized Phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Group tr